Novo Nordisk (CPSE:NOVO B) reported strong phase 3 trial results for its oral semaglutide in children and adolescents with type 2 diabetes. The company plans to file for US and EU label expansions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results